These latest successful tests and the company’s progress as well as the addition of some new top line directors and staff have made pcmb a better bet but all experimental medicines are risky investments.
The upside of this one at just 5 cents a share makes it very appealing imho.
I believe we will have early tests results in the first weeks after ind approval and they will be very good indeed.
Side effect free chemo therapy. Who wouldn’t opt for that?
In the short term for those who are happy to double or treble their money on ind submission and again on approval I think accumulation at this price is a no brainer.
It’s a vastly better company than it was a year ago before Thomas Yuen and Makowka joined.
Ind will double or treble it. Maybe more.
And according to kw we are there with ind submission.
News 
Market Data 
Discover 
